Skip to content

Understanding how COPD flare-ups change the body's recovery process

Specialised pro-RESOLVing lipid mediators in the resolution of acute Exacerbations of COPD

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN32994750
Enrollment
100
Registered
2025-11-21
Start date
2026-03-04
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease (COPD) Respiratory

Interventions

This is an observational study. The aim of this study is to investigate the effects of an acute exacerbation of COPD on resolution physiology. This study is divided into a main study and a sub-study.

Sponsors

University of Leicester
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Participant is willing and able to give informed consent for participation in the study 2. Male or Female, aged 18 years old and above 3. Able (in the Investigator's opinion) and willing to comply with all the study requirements 4. Hospitalised following an acute exacerbation

Exclusion criteria

Exclusion criteria: 1. Female participants who are pregnant or lactating 2. Participant is unwilling or unable to give informed consent for participation 3. Unable (in the Investigators opinion) or unwilling to comply with the study requirements 4. Participants who are unable to understand written and spoken English. 5. Participant has any other significant disease or disorder which, in the opinion of the Investigator may either put the participants at risk, influence their ability to participate in the study or influence the result of the study. This includes but is not limited to - respiratory diseases such as asthma, bronchiectasis, pneumonia and cancer. 6. Patients that require intubation or admission to ICU.

Design outcomes

Primary

MeasureTime frame
Levels of specialised pro-resolving mediators (SPMs) measured using the Liquid Chromatography Mass Spectrometry (LCMS) in the baseline blood sample

Secondary

MeasureTime frame
There are no secondary outcome measures

Countries

England, United Kingdom

Contacts

Public ContactOluwadamilola Yinka-Adebisi
oya3@leicester.ac.uk-

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 3, 2026